Biological Assembly 1  

 3D View: Structure | 1D-3D View | Validation Report

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 2-mer - A1B1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 22.45 kDa 
• Atom Count: 1524 
• Modelled Residue Count: 191 
• Deposited Residue Count: 199 
• Unique protein chains: 2

2KBW

Solution Structure of human Mcl-1 complexed with human Bid_BH3 peptide

• PDB DOI: 10.2210/pdb2KBW/pdb

• Classification: APOPTOSIS
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2008-12-09 Released: 2009-12-15 
• Deposition Author(s): Liu, Q., Moldoveanu, T., Sprules, T., Matta-Camacho, E., Mansur-Azzam, N., Gehring, K.

---

Experimental Data Snapshot

• Method: SOLUTION NMR
• Conformers Calculated: 200 
• Conformers Submitted: 10 
• Selection Criteria: structures with the lowest energy 

Literature

Apoptotic regulation by MCL-1 through heterodimerization.

Liu, Q., Moldoveanu, T., Sprules, T., Matta-Camacho, E., Mansur-Azzam, N., Gehring, K.

(2010) J Biol Chem 285: 19615-19624

• PubMed: 20392693 
• DOI: 10.1074/jbc.M110.105452
• Primary Citation of Related Structures:  
  2KBW


• PubMed Abstract: 
  

Myeloid cell leukemia 1 (MCL-1), an anti-apoptotic BCL-2 family member active in the preservation of mitochondrial integrity during apoptosis, has fundamental roles in development and hematopoiesis and is dysregulated in human cancers. It bears a unique, intrinsically unstructured, N-terminal sequence, which leads to its instability in cells and hinders protein production and structural characterization. Here, we present collective data from NMR spectroscopy and titration calorimetry to reveal the selectivity of MCL-1 in binding BCL-2 homology 3 (BH3) ligands of interest for mammalian biology. The N-terminal sequence weakens the BH3 interactions but does not affect selectivity. Its removal by calpain-mediated limited proteolysis results in a stable BCL-2-like core domain of MCL-1 (cMCL-1). This core is necessary and sufficient for BH3 ligand binding. Significantly, we also characterized the in vitro protein-protein interaction between cMCL-1 and activated BID by size exclusion chromatography and NMR titrations. This interaction occurs in a very slow manner in solution but is otherwise similar to the interaction between cMCL-1 and BID-BH3 peptides. We also present the solution structure of complex cMCL-1xhBID-BH3, which completes the family portrait of MCL-1 complexes and may facilitate drug discovery against human tumors.

---

Organizational Affiliation: 

Department of Biochemistry, McGill University, Montreal, Quebec H3G 1Y6, Canada.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Induced myeloid leukemia cell differentiation protein Mcl-1	A	164	Homo sapiens	Mutation(s): 0  Gene Names: MCL1, Myeloid Cell Leukemia 1, BCL2L3
UniProt & NIH Common Fund Data Resources
Find proteins for Q07820 (Homo sapiens) Explore Q07820  Go to UniProtKB:  Q07820
PHAROS:  Q07820

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details	Image
BH3-interacting domain death agonist	B	35	Homo sapiens	Mutation(s): 0  Gene Names: BID
UniProt & NIH Common Fund Data Resources
Find proteins for P55957 (Homo sapiens) Explore P55957  Go to UniProtKB:  P55957
PHAROS:  P55957

Experimental Data & Validation

Experimental Data

• Method: SOLUTION NMR
• Conformers Calculated: 200 
• Conformers Submitted: 10 
• Selection Criteria: structures with the lowest energy 
• OLDERADO: 2KBW Olderado

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2008-12-09 
• Released Date: 2009-12-15 
Deposition Author(s): Liu, Q., Moldoveanu, T., Sprules, T., Matta-Camacho, E., Mansur-Azzam, N., Gehring, K.

Revision History  

• Version 1.0: 2009-12-15
  Type: Initial release
  
• Version 1.1: 2011-07-13
  Changes: Version format compliance
• Version 1.2: 2022-03-16
  Changes: Data collection, Database references, Derived calculations